Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer

Published:2023-12 Issue: Volume:147 Page:106625
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Farlow Janice L.^ORCID,McCrary Hilary C.,Sipos Jennifer A.,Phay John E.,Konda Bhavana,Agrawal Amit

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference21 articles.

1. Management of invasive differentiated thyroid cancer;Nixon;Thyroid,2016

2. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer;Mazzaferri;Am J Med,1994

3. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013;Lim;JAMA,2017

4. Thyroid carcinoma, version 2.2022, NCCN Clinical Practice Guidelines in Oncology;Haddad;J Natl Compr Canc Netw,2022

5. Oncologic and functional outcomes following laryngectomy for locally advanced thyroid cancer;Flukes;J Surg Oncol,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Unresectable BRAF V600E, TERT-Mutated Differentiated Papillary Thyroid Cancer With Dabrafenib and Trametinib;JCEM Case Reports;2024-07-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP